| Top Down-regulated Canonical Pathways |
P-value |
| Activation of IRF by cytosolic pattern recognition receptors |
4.04E-09 |
| IL-1 signalling |
1.80E-07 |
| Recognition of bacteria and viruses by pattern recognition receptors |
5.32E-07 |
| Altered T cell and B cell signalling in rheumatoid arthritis |
1.29E-06 |
| B cell development |
6.06E-06 |
| Top Upstream Regulators |
Predicted activation |
| IFNL1 |
Inhibited |
| IFNA2 |
Inhibited |
| IL1RN |
Activated |
| TCR |
|
| IFNG |
Inhibited |
| Top Diseases and Biofunctions |
P-value |
| Antimicrobial response |
8.33E-11–1.21E-11 |
| Inflammatory response |
3.99E-03–1.21E-11 |
| Dermatological diseases and conditions |
3.32E-03–1.62E-10 |
| Cancer |
4.11E-03–6.54E-09 |
| Infectious disease |
3.32E-03–1.41E-08 |
| Top Up-regulated Canonical Pathways |
P-value |
| Allograft rejection signaling |
1.10E-08 |
| OX40 signaling pathway |
5.15E-08 |
| B cell development |
4.09E-07 |
| Antigen presentation pathway |
5.67E-07 |
| Autoimmune thyroid disease signaling |
2.03E-06 |
| Top Upstream Regulators |
Predicted activation |
| SMC3 |
Activated |
| PDLIM2 |
|
| EBI3 |
Activated |
| MYOC |
|
| NEUROG1 |
|
| Top Diseases and Biofunctions |
P-value |
| Cancer |
3.66E-02–9.72E-08 |
| Gastrointestinal disease |
3.66E-02–5.57E-06 |
| Hepatic system disease |
3.66E-02–9.11E-06 |
| Endocrine system disorders |
3.66E-02–4.62E-05 |
| Metabolic disease |
3.66E-02–4.62E-05 |
